36798-25-1 Usage
Description
C-(2-METHYL-1H-INDOL-5-YL)-METHYLAMINE is an organic compound with the chemical structure featuring a methylamine group attached to a 2-methyl-1H-indol-5-yl moiety. It serves as a key intermediate in the synthesis of various biologically active molecules, particularly those with potential applications in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
C-(2-METHYL-1H-INDOL-5-YL)-METHYLAMINE is used as a synthetic intermediate for the preparation of substituted aminopyridines and aminopyrazines. These compounds are of significant interest due to their potential as protein kinase inhibitors, which play a crucial role in the regulation of various cellular processes and are often dysregulated in diseases such as cancer. By targeting these protein kinases, substituted aminopyridines and aminopyrazines may offer therapeutic benefits in the treatment of various diseases, including cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 36798-25-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,7,9 and 8 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 36798-25:
(7*3)+(6*6)+(5*7)+(4*9)+(3*8)+(2*2)+(1*5)=161
161 % 10 = 1
So 36798-25-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H12N2/c1-7-4-9-5-8(6-11)2-3-10(9)12-7/h2-5,12H,6,11H2,1H3
36798-25-1Relevant articles and documents
SYNTHESIS OF BENZO(AMINOMETHYL)INDOLES
Muminov, A.,Yudin, L. G.,Zinchenko, E. Ya.,Romanova, N. N.,Kost, A. N.
, p. 1012 - 1015 (1985)
The benzene ring in indoles has been aminomethylated in high yield by reaction with methylolphtalimide followed by hydrazinolysis of the phtalimidomethyl derivatives.In the hydrazinolysis of one of the phtalimidomethyl compounds, an intermediate product (the amino-methylindole phtalazine) was isolated and characterized.
Positive allosteric modulators of nicotinic acetylcholine receptor
-
, (2012/10/08)
The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor.
